The DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.
Paroxetine versus Clomipramine in the Treatment of Obsessive–Compulsive Disorder
Abstract
Background: The aim was to assess the effect of a flexible dose of paroxetine, compared with clomipramine and placebo, in obsessive-compulsive disorder (OCD). Method: In a multinational randomised study, 406 subjects with OCD of at least six months duration received double-blind mediation for up to 12 weeks. Doses were adjusted according to therapeutic effect and side-effects. Primary efficacy measures were the Yale–Brown Obsessive–Compulsive Scale and the National Institute of Mental Health Obsessive–Compulsive Scale. Secondary efficacy measures were the Montgomery–åsberg Depression Rating Scale, Symptom Check-List (90), Clinical Global Impression, and Patients' Global Evaluation. Results: Paroxetine was significantly more effective than placebo, and of comparable efficacy to clomipramine. Paroxetine had significantly superior tolerability to clomipramine on three measures: CGI efficacy index, anticholinergic adverse events, and adverse events leading to withdrawal. Conclusion: Paroxetine is as effective as clomipramine in the treatment of OCD. The comparable efficacy and better tolerability of paroxetine suggest that it would be an appropriate treatment for OCD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A new depression scale designed to be sensitive to change
Montgomery, S. A., & Åsberg, M. (1979) · British Journal of Psychiatry · doi:10.1192/bjp.134.4.382 · Cited by 13,962
The Yale-Brown Obsessive Compulsive Scale: I. Development, Use, and Reliability
Goodman, W. K. (1989) · Archives of General Psychiatry · doi:10.1001/archpsyc.1989.01810110048007 · Cited by 7,712
The Yale-Brown Obsessive-Compulsive Scale: Measures of internal consistency
Kim, S. W., Dysken, M. W., Pheley, A. M., & Hoover, K. M. (1994) · Psychiatry Research · doi:10.1016/0165-1781(94)90039-6 · Cited by 2,359
The Epidemiology and Clinical Features of Obsessive Compulsive Disorder
Rasmussen, S. A., & Eisen, J. L. (1992) · Psychiatric Clinics of North America · doi:10.1016/s0193-953x(18)30205-3 · Cited by 867
The Cross National Epidemiology of obsessive-compulsive disorder
Weisman, M. M., Bland, R. C., CANINO, G. J., Greenwald, S., Hwu, H., Lee, C. K., Newman, S. C., Browne, M. A. O., Rubio-Stipec, M., WICKRAMARATNE, P. J., et al. (1994) · Max Planck Institute for Plasma Physics · Cited by 688
Compulsive buying: descriptive characteristics and psychiatric comorbidity.
Ga, C., Faber, R., de Zwaan, M., Raymond, N. C., Sm, S., Ekern, Tb, M., Crosby, R. D., Sj, C., & Ed, E. (1994) · PubMed · Cited by 664
Greist, J. H. (1995) · Archives of General Psychiatry · doi:10.1001/archpsyc.1995.03950130053006 · Cited by 500
COMFORT, EFFECTIVENESS, AND SELF-AWARENESS AS CRITERIA OF IMPROVEMENT IN PSYCHOTHERAPY
PARLOFF, M. B., KELMAN, H. C., & FRANK, J. D. (1954) · American Journal of Psychiatry · doi:10.1176/ajp.111.5.343 · Cited by 459
Tollefson, G. D. (1994) · Archives of General Psychiatry · doi:10.1001/archpsyc.1994.03950070051010 · Cited by 314
Greist, J. (1995) · Archives of General Psychiatry · doi:10.1001/archpsyc.1995.03950160039008 · Cited by 243
Cited by
Grant, B. F., Chou, S. P., Goldstein, R. B., Huang, B., Stinson, F. S., Saha, T. D., Smith, S. M., Dawson, D. S., Pulay, A. J., Pickering, R. P., et al. (2008) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v69n0404 · Cited by 1,618
Katzman, M. A., Bleau, P., Blier, P., Chokka, P., Kjernisted, K., Van Ameringen, M., & the Canadian Anxiety Guidelines Initiative Group on behalf of the Anxiety Disorders Association of Canada/Association Canadienne des troubles anxieux and McGill University (2014) · BMC Psychiatry · doi:10.1186/1471-244x-14-s1-s1 · Cited by 1,090
Axis I Comorbidity of Borderline Personality Disorder
Zanarini, M. C., Frankenburg, F. R., Dubo, E. D., Sickel, A. E., Trikha, A., Levin, A., & Reynolds, V. (1998) · American Journal of Psychiatry · doi:10.1176/ajp.155.12.1733 · Cited by 977
Stein, D. J., Costa, D. L. C., Lochner, C., Miguel, E. C., Reddy, Y. C. J., Shavitt, R. G., van den Heuvel, O. A., & Simpson, H. B. (2019) · Nature Reviews Disease Primers · doi:10.1038/s41572-019-0102-3 · Cited by 895
Bandelow, B., Zohar, J., Hollander, E., Kasper, S., Möller, H.-J., WFSBP TASK FORCE ON TREATMENT GUIDE, Bandelow, B., Zohar, J., Hollander, E., Kasper, S., et al. (2008) · The World Journal of Biological Psychiatry · doi:10.1080/15622970802465807 · Cited by 854
Self-citationGeneralized anxiety disorder: prevalence, burden, and cost to society
Wittchen, H.-U. (2002) · Depression and Anxiety · doi:10.1002/da.10065 · Cited by 733
Cognitive Inflexibility After Prefrontal Serotonin Depletion
Clarke, H. F., Dalley, J. W., Crofts, H. S., Robbins, T. W., & Roberts, A. C. (2004) · Science · doi:10.1126/science.1094987 · Cited by 632
Chudasama, Y., & Robbins, T. W. (2006) · Biological Psychology · doi:10.1016/j.biopsycho.2006.01.005 · Cited by 484
Eddy, K. T., Dutra, L., Bradley, R., & Westen, D. (2004) · Clinical Psychology Review · doi:10.1016/j.cpr.2004.08.004 · Cited by 475
Efficacy and Safety of Paroxetine Treatment for Chronic PTSD: A Fixed-Dose, Placebo-Controlled Study
Marshall, R. D., Beebe, K. L., Oldham, M., & Zaninelli, R. (2001) · American Journal of Psychiatry · doi:10.1176/appi.ajp.158.12.1982 · Cited by 432
Bourin, M., Chue, P., & Guillon, Y. (2001) · CNS Drug Reviews · doi:10.1111/j.1527-3458.2001.tb00189.x · Cited by 408
Skapinakis, P., Caldwell, D. M., Hollingworth, W., Bryden, P., Fineberg, N. A., Salkovskis, P., Welton, N. J., Baxter, H., Kessler, D., Churchill, R., et al. (2016) · The Lancet Psychiatry · doi:10.1016/s2215-0366(16)30069-4 · Cited by 407
Saxena, S. (1999) · Neuropsychopharmacology · doi:10.1016/s0893-133x(99)00082-2 · Cited by 379
Prefrontal Serotonin Depletion Affects Reversal Learning But Not Attentional Set Shifting
Clarke, H. F., Walker, S. C., Crofts, H. S., Dalley, J. W., Robbins, T. W., & Roberts, A. C. (2005) · The Journal of Neuroscience · doi:10.1523/jneurosci.3690-04.2005 · Cited by 358
Stein, D. J. (2002) · The Lancet · doi:10.1016/s0140-6736(02)09620-4 · Cited by 352
Cerebral glucose metabolism in obsessive-compulsive hoarding
Saxena, S., Brody, A. L., Maidment, K. M., Smith, E. C., Zohrabi, N., Katz, E., Baker, S. K., & Baxter, L. R. (2004) · American Journal of Psychiatry · doi:10.1176/appi.ajp.161.6.1038 · Cited by 343
Soomro, G. M., Altman, D. G., Rajagopal, S., & Oakley Browne, M. (2008) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd001765.pub3 · Cited by 342
Evidence-based pharmacotherapy of obsessive-compulsive disorder
Fineberg, N. A., Brown, A., Reghunandanan, S., & Pampaloni, I. (2012) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145711001829 · Cited by 336
Cottraux, J., Note, I., Yao, S. N., Lafont, S., Note, B., Mollard, E., Bouvard, M., Sauteraud, A., Bourgeois, M., & Dartigues, J.-F. (2001) · Psychotherapy and Psychosomatics · doi:10.1159/000056269 · Cited by 298
Paroxetine: An Update of Its Use in Psychiatric Disorders in Adults
Wagstaff, A. J., Cheer, S. M., Matheson, A. J., Ormrod, D., & Goa, K. L. (2002) · Drugs · doi:10.2165/00003495-200262040-00010 · Cited by 287
Clinical Predictors of Drug Response in Obsessive-Compulsive Disorder
Erzegovesi, S., Cavallini, M. C., Cavedini, P., Diaferia, G., Locatelli, M., & Bellodi, L. (2001) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-200110000-00006 · Cited by 224
Pharmacotherapy of Obsessive-compulsive Disorder and Obsessive-Compulsive Spectrum Disorders
Denys, D. (2006) · Psychiatric Clinics of North America · doi:10.1016/j.psc.2006.02.013 · Cited by 213
Saxena, S., Brody, A. L., Ho, M. L., Zohrabi, N., Maidment, K. M., & Baxter, L. R. (2003) · American Journal of Psychiatry · doi:10.1176/appi.ajp.160.3.522 · Cited by 210
Exposure and Response (Ritual) Prevention for Obsessive Compulsive Disorder: Therapist Guide
Foa, E. B., Yadin, E., & Lichner, T. K. (2012) · doi:10.1093/med:psych/9780195335286.001.0001 · Cited by 185
Fineberg, N. A., Hollander, E., Pallanti, S., Walitza, S., Grünblatt, E., Dell’Osso, B. M., Albert, U., Geller, D. A., Brakoulias, V., Janardhan Reddy, Y. C., et al. (2020) · International Clinical Psychopharmacology · doi:10.1097/yic.0000000000000314 · Cited by 161
Self-citationA Double Blind Comparison of Venlafaxine and Paroxetine in Obsessive-Compulsive Disorder
Denys, D., van der Wee, N., van Megen, H. J. G. M., & Westenberg, H. G. M. (2003) · Journal of Clinical Psychopharmacology · doi:10.1097/01.jcp.0000095342.32154.54 · Cited by 151
Adams, K. H., Hansen, E. S., Pinborg, L. H., Hasselbalch, S. G., Svarer, C., Holm, S., Bolwig, T. G., & Knudsen, G. M. (2005) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145705005055 · Cited by 147
“Multiple randomized, double-blind, placebocontrolled studies have demonstrated the efficacy of SSRIs alone (Jenike et al., 1990a,b ; Ravindran et al., 1999 ; Zohar and Judge, 1996).”
BackgroundUnmet need for services and interventions among adolescents with mental disorders
Wang, P. S., Sherrill, J., & Vitiello, B. (2007) · American Journal of Psychiatry · doi:10.1176/ajp.2007.164.1.1 · Cited by 123
Pharmacotherapy of obsessive–compulsive disorder: evidence-based treatment and beyond
Fineberg, N. A., Reghunandanan, S., Brown, A., & Pampaloni, I. (2013) · Australian & New Zealand Journal of Psychiatry · doi:10.1177/0004867412461958 · Cited by 122
“Zohar and Judge (1996) compared paroxetine and clomipramine, and at weeks 6, 8 and 12 showed similar placebo-referenced efficacy on OCD symptom scores, though paroxetine was superior to placebo on depression ratings whereas clomipramine was not.”
BackgroundRoest, A. M., de Jonge, P., Williams, C. D., de Vries, Y. A., Schoevers, R. A., & Turner, E. H. (2015) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2015.15 · Cited by 101
Bokor, G., & Anderson, P. D. (2014) · Journal of Pharmacy Practice · doi:10.1177/0897190014521996 · Cited by 79
Predictors of treatment response to fluvoxamine in obsessive–compulsive disorder: An fMRI study
Sanematsu, H., Nakao, T., Yoshiura, T., Nabeyama, M., Togao, O., Tomita, M., Masuda, Y., Nakatani, E., Nakagawa, A., & Kanba, S. (2010) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2009.08.007 · Cited by 68
Combining Pharmacotherapy with Cognitive‐Behavioral Interventions for Obsessive‐Compulsive Disorder
Cottraux, J., Bouvard, M. A., & Milliery, M. (2005) · Cognitive Behaviour Therapy · doi:10.1080/16506070510043750 · Cited by 60
Meta-analysis: Risk of dry mouth with second generation antidepressants
Cappetta, K., Beyer, C., Johnson, J. A., & Bloch, M. H. (2018) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2017.12.012 · Cited by 49
Ruiz (2000) · doi:10.1097/00131746-200005000-00002 · Cited by 14
Metadata
- Authors
- Zohar, J., Judge, R., & Ocd Paroxetine Study Investigators
- Venue
- British Journal of Psychiatry
- Publisher
- Royal College of Psychiatrists
- Published
- 1996-10
- Volume
- 169
- Issue
- 4
- Pages
- 468-474
- ISSN
- 0007-1250 (ISSN-L)
- 1472-1465
- OpenAlex
- W2162253908
- Cited by
- 272
- References
- 29
- FWCI
- 18.90
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.